BusinessSwitzerlandUK

Atlas of cancer cell drug sensitivity launched

30.03.2012 - Two European teams have created huge repositories of cancer genomics data that help predict drug response.

Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale sequencing data of 947 of the 1,200 commercially available human cancer cell lines with the pharmacological profiles of 24 anti-cancer drugs. (Nature 29 March) in a „Cancer Cell Line Encyclopaedia (CCLE)". The cell lines reflect the genetic disturbances that drive cancers,“ said Mark Fishman, Chief of the Novartis Institutes for BioMedical Research (NIBR) that led the study. „Probing cell lines with medicines targeted at specific pathways, as done for the CCLE, provides a powerful tool for design of cancer treatment.“ The data, put into the public domain, will help improve developing targeted therapies. The CCLE provides gene expression data, information on copy number changes as well as DNA sequence variations in about 1,600 cancer-related genes. Additionally, algorithms have been developed to predict drug responses based on the cancer cell’s molecular make-up. When a personal genome is matched against these data an optimised therapy can be obtained for this patient.

In a second study, European researchers from the cancer genome project teamed (coordination EBI, Hinxton) up with US doctors from Massachusetts General Hospital to uncover genetic biomarkers of cancer cells’ drug sensitivity against 130 compounds under clinical and preclinical development (Nature 29.3.). The study was carried out analysing 630 human tumour cell lines representing cancers of epthelial, mesenchymal and hematopoetic origin. The identified cancer subtypes and drug response profiles have been put to the public domain to help researchers engaged in the development of personalised cancer treatments. 

http://www.european-biotechnology-news.com/news/news/2012-01/atlas-of-cancer-cell-drug-sensitivity-launched.html

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR26.8%
  • VERONA PHARMA (UK)5.10 GBP17.2%
  • MEDIGENE (D)9.72 EUR16.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.9%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.9%

TOP

  • ADOCIA (F)66.29 EUR388.1%
  • 4SC (D)4.90 EUR375.7%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-69.1%

No liability assumed, Date: 02.07.2015